VA-DISYS
Digital Intelligence Systems, LLC (DISYS) and Signature Consultants, LLC announce today that an agreement was signed for DISYS to acquire the legal entities of Signature, combine operations, and create one of the largest providers of information technology (IT) staffing services in the U.S. With combined annual revenues of $860M, the organization will also be the second largest minority-owned staffing firm in the nation. Both businesses will maintain their respective brands in the marketplace for the foreseeable future.
The combined operations will draw on the resources of more than 7,500 employees and consultants, serving clients from more than 40 offices, eight countries, and four delivery centers worldwide. Together, the IT firm will offer capabilities in staffing and recruiting, managed services programs (MSPs), consulting and project management, and automation support.
The current DISYS CEO, Mahfuz Ahmed, will serve as the CEO of the combined organization. Dr. Jay Cohen, founder and former CEO of Signature, will remain with the new entity to continue his oversight of day-to-day functioning of Signature operations and to focus on the cultural integration of the newly- combined organization. The senior leadership teams of both organizations will also remain intact.
“For DISYS, combining forces with Signature is a great strategic fit for both of our organizations, this brings expanded opportunities as we continue to diversify our account portfolio and puts us within striking distance of becoming a $1B firm,” said Mahfuz Ahmed, DISYS’ CEO. “DISYS and Signature share attributes that create a synergistic whole and we believe our complementary service offering will enable us to reach new levels of growth. We are stronger together and look ahead to a bright future as we continue to set the standard for the staffing and solutions industry.”
Both companies take great pride in sharing similar values, including collaboration, respect, accountability, fairness, and ingenuity, as well as bringing deep expertise to engagements. The combined company will continue to deepen its technical leadership to deliver high quality service and client-driven results.
“DISYS’ strong operations, successful brand, core values, and exceptional industry practices make them an excellent strategic partner for us,” says Dr. Jay Cohen, founder of Signature. “The combination of our two organizations creates a powerful force in the industry, expanding our clients’ access to an even greater array of IT and professional talent and specialized services and providing enhanced opportunities for our consultants and employees to further their skill development and careers.”
The transaction will be funded through debt financing provided by Wells Fargo Bank and The Carlyle Group. Carlyle’s $56 billion Global Credit platform made the investment with capital primarily from its Credit Opportunities franchise. The Credit Opportunities franchise invests in privately negotiated capital solutions primarily for upper middle market borrowers, including both private equity sponsored and family or entrepreneur-owned companies.
Alex Popov, Carlyle’s Head of Illiquid Credit Strategies, said, “We are excited to partner with industry-leading founders at DISYS and Signature, who have built strong, complementary businesses meeting a growing need for IT staffing, and to provide capital to help them better serve clients and support strategic growth objectives.”
“Wells Fargo is proud to continue our longstanding relationship with DISYS and provide a flexible, asset-based lending solution to support this exciting growth,” said Raphael Torres, Managing Director, Wells Fargo Commercial Capital, Staffing Services Group. “We are honored to be part of this next chapter alongside DISYS’s innovative management team and to continue supporting this strong, minority-owned business with their working capital needs.”
Wells Fargo Commercial Capital continues as the asset-based lender for DISYS. Wells Fargo Securities, LLC served as the exclusive financial advisor to Signature Consultants while Deloitte Consulting provided advisory services on behalf of DISYS.
About Digital Intelligence Systems, LLC (DISYS)
DISYS, founded in 1994 and headquartered in McLean, Virginia, is a global managed services and staffing firm with 33 offices and 4 delivery centers worldwide. As a leading global enterprise, DISYS’ experts are thought leaders in the industry, who bring best-in-class expertise to more than 250 Fortune 500 companies. Recognized as a Top 20 Staffing Provider and one of the Largest Staffing Firms in the U.S., as well as a leading Diversity Staffing Firm by Staffing Industry Analysts (SIA), DISYS is also a certified Minority Business Enterprise (MBE) and Top Supplier to 7 of 10 leading global MSPs. With the support of almost 5,000 internal and external (consultant) employees, DISYS specializes in Global Staffing, Application Development Services, Business Intelligence Services, Cloud Enablement Services, Infrastructure Support Services, Enterprise Apps as-a-Service, Automated Testing, and Process Automation. For more information on the company, please visit www.disys.com .
About Signature Consultants, LLC
Headquartered in Fort Lauderdale, Florida, Signature Consultants was established in 1997 with a singular focus: to provide clients and consultants with superior staffing solutions. With 29 locations throughout North America, Signature annually deploys thousands of consultants to support, run and manage their clients’ technology needs. Signature offers IT staffing, consulting, managed solutions, and direct placement services. For more information on the company, please visit https://www.sigconsult.com . Signature Consultants is the parent company to Hunter Hollis and Madison Gunn .
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions. With $246 billion of assets under management as of December 31, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs 1,825 people in 29 offices across five continents. Further information is available at www.carlyle.com . Follow The Carlyle Group on Twitter @OneCarlyle
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005257/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom